{
  "x402Version": 2,
  "id": 4552,
  "slug": "4552",
  "resource": "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape",
  "description": "Competitive drug pipeline landscape for any disease — full Phase 2/3 trial map, mechanism-of-action coverage, approved drugs, PDUFA calendar, M&A activity, opportunity gaps and investment thesis. Worldwide. For biotech and pharma intelligence agents.",
  "type": "http",
  "accepts": [
    {
      "scheme": "exact",
      "network": "eip155:8453",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:8453",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
      "amount": "350000",
      "maxTimeoutSeconds": 604900
    },
    {
      "scheme": "exact",
      "network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
      "payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
      "asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:137",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:42161",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0xaf88d065e77c8cC2239327C5EDb3A432268e5831",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:480",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x79A02482A880bCe3F13E09da970dC34dB4cD24D1",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:143",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x754704Bc059F8C67012fEd69BC8A327a5aafb603",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:196",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x779ded0c9e1022225f8e0630b35a9b54be713736",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:999",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0xb88339CB7199b77E23DB6E890353E22632Ba630f",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k",
      "payTo": "62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I",
      "asset": "31566704",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "xrpl:0",
      "payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
      "asset": "XRP",
      "amount": "350000",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "xrpl:0",
      "payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
      "asset": "524C555344000000000000000000000000000000",
      "amount": "0.35",
      "maxTimeoutSeconds": 300
    },
    {
      "scheme": "exact",
      "network": "eip155:56",
      "payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
      "asset": "0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d",
      "amount": "350000000000000000",
      "maxTimeoutSeconds": 300
    }
  ],
  "outputSchema": {
    "bazaar": {
      "info": {
        "input": {
          "method": "GET",
          "queryParams": {
            "condition": "Disease area — e.g. \"Parkinson Disease\" | \"Breast Cancer\" | \"NASH\" | \"Heart Failure\" | \"Schizophrenia\"",
            "depth": "standard | deep (default: standard)",
            "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)"
          },
          "type": "http"
        },
        "output": {
          "example": {
            "approved_drugs": [
              {
                "approved": "2024-03",
                "indication": "NASH with moderate-to-advanced fibrosis",
                "mechanism": "THR-β agonist",
                "name": "Resmetirom (Rezdiffra)",
                "sponsor": "Madrigal Pharmaceuticals"
              }
            ],
            "deal_activity": "Highly active M&A space. AstraZeneca acquired Eccogene NASH program ($185M). Roche/Genentech building liver portfolio. Novo Nordisk GLP-1 dominance creating competitive panic.",
            "investment_thesis": "NASH market projected $18-25B by 2030. Resmetirom first approval sets pricing precedent. GLP-1 combination therapy is the likely future standard of care.",
            "key_readouts_next_18m": [
              "NASH-RESOLVE (semaglutide histology 2025)",
              "MAESTRO-NASH (lanifibranor 2025)",
              "ATLAS trial (aldafermin 2026)"
            ],
            "mechanism_landscape": {
              "crowded": [
                "FXR agonists (8 Phase 2/3)",
                "ACC inhibitors (6)",
                "FGF21 analogs (5)"
              ],
              "emerging": [
                "Pan-PPAR agonists",
                "GLP-1/GIP combinations (semaglutide expanding)"
              ],
              "opportunity_gaps": [
                "Cirrhosis reversal agents",
                "Pediatric NAFLD",
                "Combination sequential therapy protocols"
              ]
            },
            "opportunity_score": {
              "max": 100,
              "note": "Validated market with first approval. GLP-1 expansion threatening narrow competitors.",
              "rating": "High Value",
              "score": 78
            },
            "pdufa_calendar": [
              {
                "drug": "Lanifibranor",
                "mechanism": "Pan-PPAR",
                "pdufa_estimate": "2026-Q1",
                "priority_review": false,
                "sponsor": "Inventiva"
              }
            ],
            "pipeline_overview": {
              "approval_recent_12m": 1,
              "approved_drugs": 2,
              "phase2_count": 48,
              "phase3_count": 19,
              "total_active": 67
            },
            "query_summary": {
              "as_of": "2026-06-07",
              "condition": "NASH (Nonalcoholic Steatohepatitis)",
              "depth": "standard"
            },
            "top_phase3_assets": [
              {
                "completion": "2025-Q4",
                "drug": "Semaglutide 2.4mg",
                "mechanism": "GLP-1 RA",
                "nctId": "NCT04858633",
                "significance": "Blockbuster potential — NASH + obesity combined label",
                "sponsor": "Novo Nordisk"
              }
            ]
          },
          "type": "json"
        }
      },
      "schema": {
        "$schema": "https://json-schema.org/draft/2020-12/schema",
        "properties": {
          "input": {
            "additionalProperties": false,
            "properties": {
              "method": {
                "enum": [
                  "GET",
                  "HEAD",
                  "DELETE"
                ],
                "type": "string"
              },
              "queryParams": {
                "properties": {
                  "condition": {
                    "type": "string"
                  },
                  "depth": {
                    "type": "string"
                  },
                  "lang": {
                    "type": "string"
                  }
                },
                "type": "object"
              },
              "type": {
                "const": "http",
                "type": "string"
              }
            },
            "required": [
              "type",
              "method"
            ],
            "type": "object"
          },
          "output": {
            "properties": {
              "example": {
                "type": "object"
              },
              "type": {
                "type": "string"
              }
            },
            "required": [
              "type"
            ],
            "type": "object"
          }
        },
        "required": [
          "input"
        ],
        "type": "object"
      }
    },
    "builder-code": {
      "info": {
        "a": "bc_gxy6qn5p"
      },
      "schema": {
        "$schema": "https://json-schema.org/draft/2020-12/schema",
        "additionalProperties": false,
        "properties": {
          "a": {
            "description": "App builder code",
            "pattern": "^[a-z0-9_]{1,32}$",
            "type": "string"
          },
          "s": {
            "description": "Service builder codes",
            "items": {
              "pattern": "^[a-z0-9_]{1,32}$",
              "type": "string"
            },
            "type": "array"
          },
          "w": {
            "description": "Wallet builder code",
            "pattern": "^[a-z0-9_]{1,32}$",
            "type": "string"
          }
        },
        "type": "object"
      }
    }
  },
  "tags": [
    "bazaar",
    "builder-code"
  ],
  "sourceHost": "clinicalintelpulse.theaslangroupllc.com",
  "lastUpdated": "2026-08-20T14:01:56.792Z",
  "quality": {
    "calls30d": 1,
    "uniquePayers30d": 1,
    "lastCalledAt": "2026-08-20T14:01:56.613Z"
  },
  "liveness": {},
  "verified": false,
  "featured": false,
  "provider": {
    "host": "clinicalintelpulse.theaslangroupllc.com",
    "manifest_name": "clinicalintelpulse.theaslangroupllc.com",
    "source": "cdp-mirror",
    "source_manifest_url": "https://api.cdp.coinbase.com/platform/v2/x402/discovery/resources",
    "submitted_at": "2026-09-18T22:00:31.484Z"
  }
}